VYCOR MEDICAL INC 8-K

What Happened
VYCOR Medical Inc. (VYCO) filed a Form 8-K on May 15, 2026 under Item 2.02 to announce its financial results for the three months ended March 31, 2026. The company furnished a press release as Exhibit 99.1 to the Form 8-K that includes the reported quarterly results and reconciliations of non‑GAAP measures to the comparable GAAP measures. The company clarified the Item 2.02 disclosure is furnished and not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Filing date: May 15, 2026; reporting period: quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 to the Form 8-K (contains the detailed figures and reconciliations).
• Non‑GAAP measures disclosed: “non‑GAAP Cash Operating Expenses” and “non‑GAAP Cash Operating Loss,” which exclude depreciation and non‑cash stock‑based compensation.
• Company provided reconciliations from these non‑GAAP measures to the comparable GAAP measures and warned of limitations of non‑GAAP metrics.

Why It Matters
This is a routine quarterly earnings disclosure; investors should read the attached press release for the actual revenue, expense, and loss figures. The non‑GAAP cash measures show how management evaluates ongoing cash operating performance, but they exclude depreciation and stock‑based compensation and are not a substitute for GAAP results — review both GAAP and the reconciliations before drawing conclusions. The Form 8‑K does not report executive changes, mergers, or other material corporate actions.